Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC lowered its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 13.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 722,048 shares of the company’s stock after selling 108,165 shares during the quarter. Nuveen Asset Management LLC owned about 1.07% of Perspective Therapeutics worth $2,303,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in CATX. Millennium Management LLC purchased a new position in shares of Perspective Therapeutics in the fourth quarter worth about $4,132,000. Octagon Capital Advisors LP raised its position in Perspective Therapeutics by 62.1% during the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after buying an additional 882,528 shares during the last quarter. Affinity Asset Advisors LLC lifted its stake in Perspective Therapeutics by 160.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock valued at $4,147,000 after acquiring an additional 800,000 shares during the period. Walleye Capital LLC boosted its holdings in shares of Perspective Therapeutics by 2,526.2% in the 4th quarter. Walleye Capital LLC now owns 475,792 shares of the company’s stock valued at $1,518,000 after acquiring an additional 457,675 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Perspective Therapeutics in the fourth quarter worth $834,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Insider Activity

In other news, CFO Juan Graham purchased 33,333 shares of the company’s stock in a transaction that occurred on Friday, March 28th. The stock was purchased at an average cost of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the transaction, the chief financial officer now owns 35,354 shares of the company’s stock, valued at $79,546.50. This trade represents a 1,649.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Johan M. Spoor acquired 22,026 shares of Perspective Therapeutics stock in a transaction that occurred on Friday, March 28th. The stock was purchased at an average cost of $2.24 per share, with a total value of $49,338.24. Following the completion of the purchase, the chief executive officer now owns 59,383 shares in the company, valued at $133,017.92. The trade was a 58.96% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 115,696 shares of company stock worth $256,344 over the last 90 days. 3.72% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on CATX. Truist Financial decreased their target price on shares of Perspective Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday, May 13th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a report on Monday, March 31st. Scotiabank assumed coverage on Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price objective on the stock. Finally, Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $12.50.

Perspective Therapeutics Stock Down 7.0%

Shares of CATX stock opened at $2.39 on Tuesday. Perspective Therapeutics, Inc. has a 1-year low of $1.60 and a 1-year high of $16.55. The stock has a 50 day simple moving average of $2.25 and a 200-day simple moving average of $2.94.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.